Induction TNX Plus Concurrent Nedaplatin-RT Versus Induction TPF Plus Concurrent Cisplatin-RT in NPC

Condition:   Nasopharyngeal Carcinoma
Interventions:   Drug: docetaxel, nedaplatin, and capecitabine;   Drug: concurrent chemoradiotherapy with nedaplatin;   Drug: docetaxel, cisplatin, and fluorouracil;   Drug: concurrent chemoradiotherapy with cisplatin
Sponsors:   Sun Yat-sen University;   Tongji Hospital;   Wuhan Union Hospital, China;   Peking University;   Fourth Military Medical University;   Second Affiliated Hospital of Soochow University;   The First Affiliated Hospital of Guangdong Pharmaceutical University;   First People's Hospital of Foshan;   Fifth Affiliated Hospital, Sun Yat-Sen University;   Cancer Hospital of Guizhou Province;   Xiangya Hospital of Central South University;   Jilin Provincial Tumor Hospital;   Henan Cancer Hospital;   Hunan Cancer Hospital;   Cancer Hospital of Guangxi Medical University
Not yet recruiting

https://ift.tt/2HCIVKg